Immunovant Grabs Investor Attention with Graves’ Disease Clinical Success

Immunovant, Inc. (Nasdaq: IMVT) has announced positive results from its Phase 2 clinical trial of batoclimab in patients with Graves’ disease. The company reported that results from the initial cohort of patients meaningfully exceeded 50% response rates.

Pete Salzmann, M.D., chief executive officer at Immunovant, said, “We believe the enrolled population is unlikely to spontaneously remit and therefore a greater than 50% response rate is encouraging. While preliminary, these data suggest there is a dose response on efficacy between a regimen that produces 60-70% IgG reductions, such as 340 mg of batoclimab, and a regimen that produces 80% IgG reductions. We believe there is a high unmet need in second line Graves’ disease and are enthusiastic about the addressable market size here.”

While the trial is ongoing, Immunovant intends to focus on future development in Graves’ on IMVT-1402, with plans expected to be announced later in 2024.

Highlights

Immunovant’s Phase 2 proof-of-concept trial is an open-label study to assess the safety and efficacy of batoclimab in Graves’ disease. Batoclimab was generally well tolerated with no new safety signals observed to date.

Treatment response is defined as normalization of T3 and T4 hormone levels without increasing ATD dose.

Immunovant has what it believes to be the only option across the anti-FcRn field of a simple SC injection to produce this profile.

About Immunovant, Inc.

Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit www.immunovant.com.